Pharmaceutical - Sovaldi

Filter

Current filters:

Sovaldi

Popular Filters

Pharma must look to other industries for models of managing high cost of new drugs

Pharma must look to other industries for models of managing high cost of new drugs

13-03-2015

New financing approaches are required in order to account for the emerging extremely expensive drugs…

GileadPharmaceuticalPricingRAND CorporationSovaldi

2014 saw highest increase in US drug spend over past decade

2014 saw highest increase in US drug spend over past decade

10-03-2015

In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers…

Anti-viralsFinancialGilead SciencesHarvoniHealthcareJohnson & JohnsonMarkets & MarketingOlysioPharmaceuticalSovaldiUSA

NICE recommends Sovaldi and Olysio for hepatitis C

NICE recommends Sovaldi and Olysio for hepatitis C

25-02-2015

The UK’s National Institute for Health and Care Excellence (NICE) has published final guidance recommending…

Anti-viralsGilead SciencesJanssenOlysioPharmaceuticalRegulationSovaldiUK

Médecins du Monde challenges Gilead’s Sovaldi patent in EU

Médecins du Monde challenges Gilead’s Sovaldi patent in EU

11-02-2015

The high price of US biotech major Gilead Sciences’ blockbuster hepatitis C (HCV) drug Sovaldi (sofosbuvir)…

Anti-viralsEuropeGilead SciencesPharmaceuticalPricingSovaldi

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

06-01-2015

US pharmacy benefits manager CVS Health has entered into a deal with US biotech major Gilead Sciences…

GileadHarvoniNephrology and HepatologyPharmaceuticalPricingSovaldiUSA

France negotiates lowest price in Europe for Gilead’s Sovaldi

France negotiates lowest price in Europe for Gilead’s Sovaldi

21-11-2014

The discount negotiated by the French government on hepatitis C drug Sovaldi (sofosbuvir), produced by…

FranceGilead SciencesNephrology and HepatologyPharmaceuticalPoliticsPricingRegulationSovaldi

Bristol-Myers’ hep C drug Daklinza approved in Europe

Bristol-Myers’ hep C drug Daklinza approved in Europe

27-08-2014

US pharma major Bristol-Myers Squibb says that the European Commission has approved Daklinza (daclatasvir),…

Anti-viralsBristol-Myers SquibbDaklinzaEuropeGilead SciencesPharmaceuticalRegulationSovaldi

Achillion soars on positive mid-stage hep C drug combo trial

Achillion soars on positive mid-stage hep C drug combo trial

17-08-2014

US drugmaker Achillion saw its share rocket 18.4% to a 52-week high of $9.99 in pre-market trading on…

ACH-3102AchillionAnti-viralsHepatitis C virusPharmaceuticalResearchsofosbuvirSovaldiUSA

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs

17-07-2014

State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

17-01-2014

Since the US Food and Drug Administration’s breakthrough therapy designation (BTD) was put into effect…

GazyvaGilead SciencesImbruvicaJohnson & JohnsonPharmaceuticalRegulationRocheSovaldiUSA

Back to top